William Steinbach
Concepts (501)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Aspergillus fumigatus | 54 | 2021 | 102 | 21.370 |
Why?
| Antifungal Agents | 90 | 2023 | 363 | 15.360 |
Why?
| Fungal Proteins | 30 | 2021 | 133 | 10.680 |
Why?
| Aspergillosis | 48 | 2020 | 127 | 10.120 |
Why?
| Calcineurin | 28 | 2022 | 70 | 9.370 |
Why?
| Echinocandins | 35 | 2017 | 64 | 5.440 |
Why?
| Hyphae | 17 | 2018 | 32 | 5.370 |
Why?
| Mycoses | 28 | 2023 | 162 | 4.820 |
Why?
| Cell Wall | 17 | 2020 | 73 | 3.660 |
Why?
| HSP90 Heat-Shock Proteins | 10 | 2016 | 53 | 3.650 |
Why?
| Lipopeptides | 29 | 2017 | 64 | 2.830 |
Why?
| Tacrolimus | 15 | 2022 | 52 | 2.720 |
Why?
| Candidiasis | 23 | 2022 | 122 | 2.690 |
Why?
| Fungi | 11 | 2016 | 48 | 2.680 |
Why?
| Gene Expression Regulation, Fungal | 12 | 2019 | 58 | 2.650 |
Why?
| Aspergillus | 15 | 2017 | 51 | 2.630 |
Why?
| Drug Resistance, Fungal | 14 | 2023 | 34 | 2.560 |
Why?
| Septins | 5 | 2017 | 19 | 2.530 |
Why?
| Tacrolimus Binding Protein 1A | 7 | 2022 | 14 | 2.370 |
Why?
| Hematopoietic Stem Cell Transplantation | 18 | 2023 | 583 | 2.360 |
Why?
| Candidiasis, Invasive | 5 | 2023 | 7 | 2.300 |
Why?
| Candida | 14 | 2022 | 67 | 2.160 |
Why?
| Spores, Fungal | 7 | 2018 | 21 | 2.070 |
Why?
| Cyclic AMP-Dependent Protein Kinases | 3 | 2020 | 56 | 1.950 |
Why?
| beta-Glucans | 9 | 2022 | 26 | 1.930 |
Why?
| Cryptococcus neoformans | 6 | 2023 | 28 | 1.870 |
Why?
| Peptides, Cyclic | 14 | 2007 | 44 | 1.780 |
Why?
| Pediatrics | 7 | 2018 | 323 | 1.720 |
Why?
| Invasive Pulmonary Aspergillosis | 5 | 2017 | 12 | 1.600 |
Why?
| Mannans | 6 | 2017 | 16 | 1.560 |
Why?
| Triazoles | 16 | 2021 | 119 | 1.540 |
Why?
| Child | 55 | 2023 | 7368 | 1.540 |
Why?
| Virulence | 11 | 2020 | 196 | 1.460 |
Why?
| Humans | 141 | 2023 | 54397 | 1.450 |
Why?
| Fungemia | 8 | 2015 | 36 | 1.420 |
Why?
| Mucormycosis | 5 | 2021 | 28 | 1.410 |
Why?
| Myosin Type V | 2 | 2020 | 6 | 1.390 |
Why?
| Phosphorylation | 8 | 2020 | 613 | 1.390 |
Why?
| Microbial Sensitivity Tests | 15 | 2023 | 290 | 1.340 |
Why?
| Mutation | 10 | 2020 | 1504 | 1.190 |
Why?
| Chitin Synthase | 3 | 2011 | 6 | 1.180 |
Why?
| Protein Processing, Post-Translational | 4 | 2017 | 183 | 1.150 |
Why?
| Immunocompromised Host | 11 | 2020 | 130 | 1.130 |
Why?
| Opportunistic Infections | 6 | 2017 | 58 | 1.090 |
Why?
| Child, Preschool | 31 | 2021 | 4158 | 1.010 |
Why?
| Azoles | 7 | 2020 | 28 | 0.980 |
Why?
| Calcium | 4 | 2019 | 434 | 0.970 |
Why?
| Protein Multimerization | 3 | 2020 | 54 | 0.950 |
Why?
| Stress, Physiological | 6 | 2019 | 194 | 0.950 |
Why?
| Adolescent | 35 | 2022 | 6901 | 0.930 |
Why?
| Animals | 32 | 2023 | 14411 | 0.910 |
Why?
| Gene Expression Regulation, Enzymologic | 2 | 2017 | 206 | 0.890 |
Why?
| Amphotericin B | 12 | 2023 | 122 | 0.890 |
Why?
| Amino Acid Sequence | 11 | 2021 | 767 | 0.870 |
Why?
| Mice | 18 | 2023 | 6429 | 0.850 |
Why?
| Pyrimidines | 11 | 2011 | 196 | 0.840 |
Why?
| Chitin | 3 | 2011 | 6 | 0.840 |
Why?
| Candida albicans | 7 | 2019 | 34 | 0.830 |
Why?
| Virus Diseases | 2 | 2019 | 44 | 0.820 |
Why?
| Proteome | 2 | 2020 | 178 | 0.820 |
Why?
| Prodrugs | 1 | 2021 | 33 | 0.800 |
Why?
| ras Proteins | 2 | 2012 | 70 | 0.800 |
Why?
| Respiratory Tract Infections | 2 | 2019 | 86 | 0.790 |
Why?
| DNA, Fungal | 3 | 2017 | 42 | 0.780 |
Why?
| Infant | 27 | 2021 | 3830 | 0.770 |
Why?
| COP-Coated Vesicles | 1 | 2020 | 6 | 0.750 |
Why?
| Catalytic Domain | 3 | 2017 | 61 | 0.730 |
Why?
| Cyclosporine | 8 | 2017 | 66 | 0.720 |
Why?
| Morphogenesis | 2 | 2012 | 20 | 0.710 |
Why?
| Drug Discovery | 2 | 2019 | 90 | 0.700 |
Why?
| Actins | 3 | 2018 | 132 | 0.680 |
Why?
| Antigens, Fungal | 3 | 2022 | 31 | 0.670 |
Why?
| Training Support | 1 | 2018 | 14 | 0.670 |
Why?
| Neoplasms | 9 | 2020 | 1322 | 0.670 |
Why?
| Organ Transplantation | 5 | 2020 | 49 | 0.660 |
Why?
| Male | 45 | 2020 | 27348 | 0.660 |
Why?
| Protein Binding | 5 | 2020 | 736 | 0.650 |
Why?
| Gene Deletion | 6 | 2017 | 293 | 0.650 |
Why?
| Disease Models, Animal | 8 | 2017 | 1648 | 0.650 |
Why?
| Practice Guidelines as Topic | 3 | 2017 | 489 | 0.620 |
Why?
| Ribosomal Proteins | 1 | 2017 | 32 | 0.620 |
Why?
| Fellowships and Scholarships | 1 | 2018 | 117 | 0.610 |
Why?
| Protein Interaction Maps | 1 | 2017 | 25 | 0.600 |
Why?
| Molecular Sequence Data | 8 | 2016 | 980 | 0.590 |
Why?
| Aminoglycosides | 5 | 2010 | 22 | 0.580 |
Why?
| Signal Transduction | 8 | 2016 | 1754 | 0.580 |
Why?
| Infant, Newborn | 21 | 2020 | 2924 | 0.580 |
Why?
| Immunosuppressive Agents | 6 | 2022 | 248 | 0.570 |
Why?
| Myosins | 1 | 2016 | 19 | 0.570 |
Why?
| Hospitalization | 3 | 2019 | 704 | 0.550 |
Why?
| Protein Transport | 5 | 2018 | 195 | 0.540 |
Why?
| Galactose | 6 | 2017 | 29 | 0.530 |
Why?
| Prospective Studies | 10 | 2022 | 2606 | 0.520 |
Why?
| Transcription Factors | 4 | 2019 | 622 | 0.520 |
Why?
| HSP70 Heat-Shock Proteins | 1 | 2015 | 61 | 0.520 |
Why?
| Molecular Chaperones | 1 | 2015 | 64 | 0.520 |
Why?
| Microscopy, Fluorescence | 4 | 2020 | 198 | 0.500 |
Why?
| Cell Division | 1 | 2015 | 330 | 0.490 |
Why?
| Drug Therapy, Combination | 8 | 2012 | 426 | 0.490 |
Why?
| Sepsis | 2 | 2015 | 250 | 0.480 |
Why?
| Enzyme Inhibitors | 2 | 2015 | 446 | 0.480 |
Why?
| Otitis Media | 3 | 2003 | 30 | 0.480 |
Why?
| Scedosporium | 2 | 2003 | 5 | 0.480 |
Why?
| Promoter Regions, Genetic | 2 | 2013 | 520 | 0.470 |
Why?
| Pathology, Molecular | 1 | 2013 | 24 | 0.470 |
Why?
| Models, Biological | 2 | 2018 | 825 | 0.470 |
Why?
| Sensitivity and Specificity | 7 | 2022 | 922 | 0.460 |
Why?
| Transcriptional Activation | 1 | 2013 | 134 | 0.460 |
Why?
| Lysine | 1 | 2014 | 102 | 0.450 |
Why?
| Lipoproteins | 4 | 2005 | 45 | 0.450 |
Why?
| Tubulin | 1 | 2013 | 28 | 0.450 |
Why?
| Genes, Fungal | 3 | 2010 | 39 | 0.450 |
Why?
| United States | 13 | 2023 | 5209 | 0.440 |
Why?
| Internship and Residency | 3 | 2004 | 501 | 0.430 |
Why?
| Treatment Outcome | 15 | 2023 | 5612 | 0.430 |
Why?
| Drug Delivery Systems | 1 | 2013 | 151 | 0.410 |
Why?
| Lung | 6 | 2016 | 508 | 0.410 |
Why?
| Risk Factors | 14 | 2023 | 3937 | 0.410 |
Why?
| Cell Membrane | 4 | 2017 | 279 | 0.400 |
Why?
| Clostridium Infections | 2 | 2023 | 62 | 0.400 |
Why?
| Cell Polarity | 1 | 2011 | 19 | 0.400 |
Why?
| Neutropenia | 4 | 2020 | 120 | 0.390 |
Why?
| Pulmonary Surfactant-Associated Protein D | 1 | 2010 | 1 | 0.380 |
Why?
| Microbial Viability | 3 | 2016 | 34 | 0.380 |
Why?
| Drug Therapy | 1 | 2010 | 50 | 0.370 |
Why?
| Candidemia | 2 | 2023 | 5 | 0.370 |
Why?
| Green Fluorescent Proteins | 3 | 2017 | 110 | 0.370 |
Why?
| Calcium-Transporting ATPases | 1 | 2010 | 11 | 0.370 |
Why?
| Cations | 1 | 2010 | 15 | 0.370 |
Why?
| Peptides | 4 | 2004 | 276 | 0.370 |
Why?
| Female | 28 | 2020 | 28474 | 0.370 |
Why?
| Amino Acid Motifs | 3 | 2016 | 57 | 0.360 |
Why?
| Peptide Synthases | 2 | 2006 | 5 | 0.360 |
Why?
| Protein Structure, Tertiary | 4 | 2015 | 289 | 0.360 |
Why?
| Clinical Trials as Topic | 6 | 2015 | 491 | 0.340 |
Why?
| Mutant Proteins | 2 | 2020 | 41 | 0.340 |
Why?
| Biguanides | 2 | 2011 | 2 | 0.340 |
Why?
| Genes, ras | 1 | 2008 | 48 | 0.340 |
Why?
| Golgi Apparatus | 2 | 2010 | 120 | 0.340 |
Why?
| Cross Infection | 3 | 2017 | 109 | 0.330 |
Why?
| Lung Diseases, Fungal | 2 | 2008 | 31 | 0.330 |
Why?
| Homeostasis | 1 | 2010 | 223 | 0.330 |
Why?
| Chromatography, Liquid | 3 | 2017 | 243 | 0.330 |
Why?
| Mutagenesis, Site-Directed | 2 | 2019 | 117 | 0.320 |
Why?
| Anti-Bacterial Agents | 7 | 2020 | 825 | 0.320 |
Why?
| Meningitis, Cryptococcal | 1 | 2007 | 12 | 0.310 |
Why?
| Sequence Deletion | 3 | 2018 | 99 | 0.310 |
Why?
| Otolaryngology | 3 | 2004 | 58 | 0.310 |
Why?
| Evolution, Molecular | 1 | 2008 | 103 | 0.300 |
Why?
| Binding Sites | 2 | 2019 | 440 | 0.300 |
Why?
| Models, Molecular | 3 | 2017 | 423 | 0.300 |
Why?
| Endocarditis | 2 | 2004 | 33 | 0.300 |
Why?
| Polyenes | 2 | 2023 | 4 | 0.300 |
Why?
| Polymerase Chain Reaction | 3 | 2017 | 531 | 0.290 |
Why?
| Gliotoxin | 1 | 2006 | 1 | 0.290 |
Why?
| Lepidoptera | 2 | 2017 | 6 | 0.290 |
Why?
| Proteomics | 2 | 2020 | 343 | 0.280 |
Why?
| Tandem Mass Spectrometry | 2 | 2017 | 248 | 0.270 |
Why?
| Conserved Sequence | 2 | 2018 | 57 | 0.270 |
Why?
| Biopsy | 2 | 2020 | 692 | 0.270 |
Why?
| Incidence | 5 | 2018 | 1084 | 0.260 |
Why?
| Protein Subunits | 2 | 2018 | 85 | 0.260 |
Why?
| Otitis Media with Effusion | 2 | 2004 | 16 | 0.250 |
Why?
| Microtubules | 2 | 2018 | 57 | 0.250 |
Why?
| Antibiotic Prophylaxis | 3 | 2020 | 67 | 0.250 |
Why?
| Mitosporic Fungi | 1 | 2004 | 2 | 0.240 |
Why?
| Time Factors | 6 | 2023 | 3210 | 0.240 |
Why?
| Otoscopy | 1 | 2004 | 4 | 0.240 |
Why?
| Mycology | 1 | 2003 | 2 | 0.240 |
Why?
| Medical Laboratory Personnel | 1 | 2003 | 5 | 0.240 |
Why?
| Mycetoma | 1 | 2003 | 1 | 0.240 |
Why?
| Sterols | 1 | 2023 | 8 | 0.240 |
Why?
| Pulmonary Aspergillosis | 3 | 2015 | 6 | 0.240 |
Why?
| Adult | 17 | 2023 | 14210 | 0.230 |
Why?
| Education, Medical, Continuing | 1 | 2003 | 79 | 0.230 |
Why?
| Communicable Diseases, Emerging | 1 | 2003 | 14 | 0.230 |
Why?
| Egtazic Acid | 2 | 2015 | 16 | 0.230 |
Why?
| Clinical Competence | 2 | 2004 | 444 | 0.230 |
Why?
| Bacteremia | 2 | 2020 | 104 | 0.230 |
Why?
| Inflammatory Bowel Diseases | 1 | 2023 | 57 | 0.230 |
Why?
| Lactams, Macrocyclic | 2 | 2012 | 14 | 0.220 |
Why?
| Ergosterol | 2 | 2023 | 8 | 0.220 |
Why?
| Benzoquinones | 2 | 2012 | 33 | 0.220 |
Why?
| Stem Cell Transplantation | 1 | 2004 | 201 | 0.220 |
Why?
| Mucorales | 2 | 2020 | 10 | 0.220 |
Why?
| Education, Medical | 1 | 2003 | 104 | 0.220 |
Why?
| Sequence Alignment | 3 | 2021 | 146 | 0.210 |
Why?
| Colony Count, Microbial | 2 | 2016 | 66 | 0.210 |
Why?
| Models, Statistical | 1 | 2004 | 259 | 0.210 |
Why?
| Mucor | 1 | 2021 | 8 | 0.210 |
Why?
| Osteomyelitis | 1 | 2003 | 124 | 0.210 |
Why?
| Educational Measurement | 1 | 2004 | 232 | 0.210 |
Why?
| Dose-Response Relationship, Drug | 4 | 2020 | 1477 | 0.210 |
Why?
| Isoxazoles | 1 | 2021 | 16 | 0.200 |
Why?
| Gene Expression | 2 | 2017 | 664 | 0.200 |
Why?
| Cryptococcosis | 2 | 2019 | 21 | 0.200 |
Why?
| Adrenal Cortex Hormones | 2 | 2018 | 95 | 0.200 |
Why?
| Bacteriological Techniques | 1 | 2001 | 38 | 0.200 |
Why?
| Adenoviridae Infections | 1 | 2020 | 5 | 0.200 |
Why?
| Dwarfism | 1 | 2000 | 4 | 0.200 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2017 | 79 | 0.190 |
Why?
| Cardiomegaly | 1 | 2000 | 38 | 0.190 |
Why?
| Debridement | 1 | 2020 | 54 | 0.190 |
Why?
| Tomography, X-Ray Computed | 2 | 2020 | 1222 | 0.190 |
Why?
| Drug Resistance, Microbial | 4 | 2007 | 51 | 0.190 |
Why?
| Salvage Therapy | 1 | 2020 | 145 | 0.180 |
Why?
| Retrospective Studies | 8 | 2020 | 6460 | 0.180 |
Why?
| Deafness | 1 | 2000 | 32 | 0.180 |
Why?
| Transcription, Genetic | 2 | 2012 | 418 | 0.180 |
Why?
| Bacterial Infections | 1 | 2001 | 105 | 0.180 |
Why?
| Protein Structure, Secondary | 1 | 2020 | 99 | 0.180 |
Why?
| Phenotype | 2 | 2018 | 819 | 0.180 |
Why?
| Coccidioides | 1 | 2019 | 3 | 0.180 |
Why?
| Mice, Inbred A | 1 | 2019 | 12 | 0.180 |
Why?
| Sequence Homology, Amino Acid | 2 | 2018 | 180 | 0.180 |
Why?
| Biological Transport | 1 | 2020 | 195 | 0.180 |
Why?
| Kaplan-Meier Estimate | 2 | 2012 | 514 | 0.180 |
Why?
| Cells, Cultured | 2 | 2023 | 1737 | 0.180 |
Why?
| Molecular Dynamics Simulation | 1 | 2019 | 40 | 0.180 |
Why?
| Cytochrome P-450 Enzyme System | 1 | 2020 | 192 | 0.170 |
Why?
| Active Transport, Cell Nucleus | 1 | 2019 | 45 | 0.170 |
Why?
| Cohort Studies | 6 | 2023 | 1547 | 0.170 |
Why?
| Crystallography, X-Ray | 1 | 2019 | 178 | 0.170 |
Why?
| Cord Blood Stem Cell Transplantation | 1 | 2018 | 5 | 0.170 |
Why?
| International Cooperation | 2 | 2012 | 62 | 0.170 |
Why?
| Abnormalities, Multiple | 1 | 2000 | 162 | 0.170 |
Why?
| Survival Rate | 4 | 2018 | 954 | 0.170 |
Why?
| Calcium Signaling | 1 | 2019 | 59 | 0.170 |
Why?
| Computer Simulation | 1 | 2020 | 332 | 0.170 |
Why?
| Drug Interactions | 3 | 2010 | 206 | 0.170 |
Why?
| Curriculum | 1 | 2002 | 434 | 0.170 |
Why?
| National Institutes of Health (U.S.) | 1 | 2018 | 49 | 0.160 |
Why?
| Luminescent Proteins | 1 | 2018 | 66 | 0.160 |
Why?
| Respiratory Therapy | 1 | 2018 | 38 | 0.160 |
Why?
| Kidney | 1 | 2023 | 822 | 0.160 |
Why?
| Insulin Resistance | 1 | 2000 | 300 | 0.160 |
Why?
| Molecular Sequence Annotation | 1 | 2017 | 31 | 0.160 |
Why?
| Leukemia, Myeloid, Acute | 3 | 2020 | 192 | 0.160 |
Why?
| Drug Synergism | 3 | 2011 | 171 | 0.160 |
Why?
| Glucosyltransferases | 1 | 2017 | 10 | 0.160 |
Why?
| Acetylation | 1 | 2018 | 99 | 0.160 |
Why?
| Immunoprecipitation | 1 | 2017 | 73 | 0.160 |
Why?
| Antibodies, Fungal | 1 | 2017 | 4 | 0.160 |
Why?
| Consensus Development Conferences as Topic | 1 | 2017 | 12 | 0.160 |
Why?
| Genes, Reporter | 1 | 2017 | 98 | 0.160 |
Why?
| Mass Spectrometry | 1 | 2019 | 313 | 0.160 |
Why?
| Immunoassay | 1 | 2017 | 31 | 0.150 |
Why?
| Protein Interaction Mapping | 1 | 2017 | 44 | 0.150 |
Why?
| Inpatients | 1 | 2019 | 206 | 0.150 |
Why?
| Myeloid Cells | 1 | 2017 | 38 | 0.150 |
Why?
| Intensive Care Units, Pediatric | 2 | 2017 | 187 | 0.150 |
Why?
| Blood Proteins | 1 | 2017 | 100 | 0.150 |
Why?
| Registries | 2 | 2012 | 554 | 0.150 |
Why?
| Logistic Models | 4 | 2023 | 991 | 0.150 |
Why?
| Structure-Activity Relationship | 1 | 2018 | 423 | 0.140 |
Why?
| Diabetes Mellitus | 1 | 2000 | 309 | 0.140 |
Why?
| Candida glabrata | 1 | 2016 | 3 | 0.140 |
Why?
| Protein Conformation | 1 | 2017 | 226 | 0.140 |
Why?
| Cyclophilin A | 1 | 2016 | 2 | 0.140 |
Why?
| DNA Mutational Analysis | 1 | 2017 | 217 | 0.140 |
Why?
| Age Factors | 4 | 2018 | 1199 | 0.140 |
Why?
| Phylogeny | 2 | 2015 | 269 | 0.140 |
Why?
| Gene Knockout Techniques | 1 | 2016 | 45 | 0.140 |
Why?
| Moths | 1 | 2015 | 7 | 0.140 |
Why?
| Escherichia coli | 1 | 2017 | 250 | 0.140 |
Why?
| Flucytosine | 2 | 2005 | 13 | 0.130 |
Why?
| Drug Tolerance | 1 | 2015 | 60 | 0.130 |
Why?
| Substrate Specificity | 1 | 2016 | 209 | 0.130 |
Why?
| Biomedical Research | 1 | 2018 | 241 | 0.130 |
Why?
| Heat-Shock Response | 1 | 2015 | 29 | 0.130 |
Why?
| Middle Aged | 9 | 2012 | 13083 | 0.130 |
Why?
| Bronchoalveolar Lavage | 1 | 2015 | 12 | 0.130 |
Why?
| Intracellular Space | 1 | 2014 | 31 | 0.130 |
Why?
| Safety | 2 | 2005 | 92 | 0.130 |
Why?
| Hematologic Neoplasms | 2 | 2017 | 100 | 0.130 |
Why?
| Decision Support Techniques | 1 | 2015 | 73 | 0.130 |
Why?
| Chemistry, Pharmaceutical | 2 | 2005 | 39 | 0.130 |
Why?
| Databases, Factual | 3 | 2007 | 683 | 0.130 |
Why?
| Randomized Controlled Trials as Topic | 3 | 2022 | 594 | 0.120 |
Why?
| Lung Diseases | 1 | 2015 | 86 | 0.120 |
Why?
| Aged | 8 | 2012 | 10061 | 0.120 |
Why?
| Mice, Inbred C57BL | 1 | 2019 | 2001 | 0.120 |
Why?
| Virulence Factors | 2 | 2022 | 94 | 0.120 |
Why?
| Acoustic Impedance Tests | 2 | 2004 | 8 | 0.120 |
Why?
| Graft vs Host Disease | 3 | 2018 | 84 | 0.110 |
Why?
| Patient Selection | 3 | 2020 | 284 | 0.110 |
Why?
| Drug Resistance, Multiple, Fungal | 1 | 2012 | 2 | 0.110 |
Why?
| Drug Design | 2 | 2021 | 133 | 0.110 |
Why?
| Transplantation, Homologous | 2 | 2020 | 154 | 0.110 |
Why?
| Epidemiologic Studies | 1 | 2012 | 30 | 0.110 |
Why?
| Culture Media | 2 | 2010 | 100 | 0.110 |
Why?
| Europe | 1 | 2012 | 102 | 0.110 |
Why?
| Lipoylation | 1 | 2012 | 3 | 0.110 |
Why?
| Serine C-Palmitoyltransferase | 1 | 2012 | 7 | 0.110 |
Why?
| Carrier Proteins | 1 | 2014 | 360 | 0.110 |
Why?
| Palmitates | 1 | 2012 | 28 | 0.110 |
Why?
| Cytosol | 1 | 2012 | 101 | 0.110 |
Why?
| Infant, Premature, Diseases | 2 | 2017 | 93 | 0.100 |
Why?
| Corneal Ulcer | 1 | 2011 | 6 | 0.100 |
Why?
| Fever | 1 | 2012 | 129 | 0.100 |
Why?
| Eye Infections, Fungal | 1 | 2011 | 22 | 0.100 |
Why?
| Cytoplasm | 1 | 2011 | 109 | 0.100 |
Why?
| Drug Dosage Calculations | 1 | 2011 | 11 | 0.100 |
Why?
| Cell Shape | 1 | 2011 | 23 | 0.100 |
Why?
| Metabolic Clearance Rate | 1 | 2011 | 75 | 0.100 |
Why?
| Glycoside Hydrolases | 1 | 2010 | 27 | 0.100 |
Why?
| Acute Disease | 2 | 2002 | 403 | 0.100 |
Why?
| Immunologic Deficiency Syndromes | 2 | 2017 | 21 | 0.100 |
Why?
| Cell Proliferation | 2 | 2017 | 1097 | 0.090 |
Why?
| Cricetulus | 1 | 2010 | 102 | 0.090 |
Why?
| Sorbitol | 1 | 2010 | 5 | 0.090 |
Why?
| CHO Cells | 1 | 2010 | 123 | 0.090 |
Why?
| Cricetinae | 1 | 2010 | 209 | 0.090 |
Why?
| Young Adult | 5 | 2022 | 4319 | 0.090 |
Why?
| Saline Solution, Hypertonic | 1 | 2010 | 18 | 0.090 |
Why?
| DNA Primers | 1 | 2010 | 225 | 0.090 |
Why?
| Hydrogen-Ion Concentration | 1 | 2010 | 194 | 0.090 |
Why?
| Administration, Oral | 2 | 2021 | 461 | 0.090 |
Why?
| Mice, Inbred Strains | 1 | 2010 | 199 | 0.090 |
Why?
| Fluconazole | 2 | 2009 | 35 | 0.090 |
Why?
| Genome, Fungal | 2 | 2006 | 43 | 0.090 |
Why?
| Fatal Outcome | 3 | 2004 | 225 | 0.090 |
Why?
| Disinfectants | 2 | 2011 | 12 | 0.080 |
Why?
| Esophageal Diseases | 1 | 2009 | 24 | 0.080 |
Why?
| Aged, 80 and over | 3 | 2023 | 3431 | 0.080 |
Why?
| Drug Approval | 2 | 2006 | 47 | 0.080 |
Why?
| Intensive Care Units, Neonatal | 3 | 2005 | 117 | 0.080 |
Why?
| Base Sequence | 1 | 2010 | 719 | 0.080 |
Why?
| Zinc Fingers | 1 | 2008 | 21 | 0.080 |
Why?
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2008 | 2 | 0.080 |
Why?
| Glucose | 1 | 2010 | 366 | 0.080 |
Why?
| Fluorescent Dyes | 1 | 2008 | 116 | 0.080 |
Why?
| Up-Regulation | 1 | 2010 | 509 | 0.080 |
Why?
| Microbiological Techniques | 1 | 2007 | 11 | 0.080 |
Why?
| Coronary Disease | 1 | 1988 | 166 | 0.080 |
Why?
| Flow Cytometry | 1 | 2010 | 547 | 0.070 |
Why?
| Trans-Activators | 1 | 2008 | 147 | 0.070 |
Why?
| Meningitis, Bacterial | 1 | 2006 | 9 | 0.070 |
Why?
| Professional Misconduct | 1 | 2006 | 6 | 0.070 |
Why?
| Neuroaspergillosis | 1 | 2006 | 1 | 0.070 |
Why?
| Infectious Disease Medicine | 2 | 2016 | 5 | 0.070 |
Why?
| Mice, Inbred ICR | 1 | 2006 | 25 | 0.070 |
Why?
| Blood-Borne Pathogens | 1 | 2006 | 8 | 0.070 |
Why?
| Cell Degranulation | 1 | 2006 | 4 | 0.070 |
Why?
| Predictive Value of Tests | 2 | 2007 | 1045 | 0.070 |
Why?
| Animals, Outbred Strains | 1 | 2006 | 13 | 0.070 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 314 | 0.070 |
Why?
| Mice, Inbred DBA | 1 | 2006 | 46 | 0.070 |
Why?
| Saccharomyces cerevisiae Proteins | 1 | 2008 | 170 | 0.070 |
Why?
| Ethics, Research | 1 | 2006 | 41 | 0.070 |
Why?
| Multigene Family | 1 | 2006 | 54 | 0.070 |
Why?
| Proportional Hazards Models | 2 | 2004 | 430 | 0.070 |
Why?
| Mast Cells | 1 | 2006 | 64 | 0.070 |
Why?
| Regression Analysis | 2 | 2004 | 445 | 0.070 |
Why?
| Radiography | 2 | 1985 | 526 | 0.070 |
Why?
| Costs and Cost Analysis | 1 | 2006 | 109 | 0.070 |
Why?
| Itraconazole | 1 | 2005 | 45 | 0.070 |
Why?
| Thiazoles | 1 | 2005 | 61 | 0.070 |
Why?
| Societies, Medical | 2 | 2016 | 195 | 0.060 |
Why?
| Internet | 1 | 2007 | 275 | 0.060 |
Why?
| DNA-Binding Proteins | 1 | 2008 | 462 | 0.060 |
Why?
| Radiographic Image Enhancement | 2 | 1984 | 32 | 0.060 |
Why?
| Multivariate Analysis | 3 | 2019 | 643 | 0.060 |
Why?
| Candidiasis, Chronic Mucocutaneous | 1 | 2004 | 2 | 0.060 |
Why?
| Candida tropicalis | 1 | 2004 | 2 | 0.060 |
Why?
| Down-Regulation | 1 | 2006 | 388 | 0.060 |
Why?
| Radiation Dosage | 2 | 1983 | 170 | 0.060 |
Why?
| Administration, Inhalation | 1 | 2004 | 119 | 0.060 |
Why?
| Case-Control Studies | 2 | 2020 | 1229 | 0.060 |
Why?
| Serial Passage | 1 | 2023 | 5 | 0.060 |
Why?
| Granulocytes | 1 | 2003 | 27 | 0.060 |
Why?
| Mice, Inbred BALB C | 2 | 2017 | 370 | 0.060 |
Why?
| Meninges | 1 | 2003 | 13 | 0.060 |
Why?
| Brain Abscess | 1 | 2003 | 11 | 0.060 |
Why?
| Ascomycota | 1 | 2003 | 11 | 0.060 |
Why?
| Administration, Topical | 1 | 2003 | 71 | 0.060 |
Why?
| Fluoroscopy | 3 | 1984 | 45 | 0.060 |
Why?
| Infant, Premature | 3 | 2017 | 337 | 0.060 |
Why?
| Infant, Very Low Birth Weight | 1 | 2003 | 47 | 0.060 |
Why?
| Occupational Medicine | 1 | 1983 | 3 | 0.060 |
Why?
| Feces | 1 | 2023 | 137 | 0.060 |
Why?
| Cholesterol | 1 | 2023 | 155 | 0.060 |
Why?
| Glucosamine | 1 | 1982 | 13 | 0.050 |
Why?
| Otoscopes | 1 | 2002 | 1 | 0.050 |
Why?
| Horse Diseases | 1 | 1982 | 17 | 0.050 |
Why?
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 1983 | 87 | 0.050 |
Why?
| Kinetics | 1 | 2023 | 692 | 0.050 |
Why?
| Canada | 1 | 2002 | 104 | 0.050 |
Why?
| Nasopharynx | 1 | 2021 | 32 | 0.050 |
Why?
| Cell Line, Tumor | 1 | 2006 | 1552 | 0.050 |
Why?
| Viral Load | 1 | 2021 | 86 | 0.050 |
Why?
| Radiography, Thoracic | 1 | 1981 | 69 | 0.050 |
Why?
| Arthritis, Rheumatoid | 1 | 1982 | 130 | 0.050 |
Why?
| Haemophilus influenzae | 1 | 2001 | 21 | 0.050 |
Why?
| Meningitis, Haemophilus | 1 | 2001 | 9 | 0.050 |
Why?
| Immunotherapy | 1 | 2003 | 264 | 0.050 |
Why?
| Nitriles | 1 | 2021 | 69 | 0.050 |
Why?
| Anus, Imperforate | 1 | 2000 | 8 | 0.050 |
Why?
| Adenoviridae | 1 | 2020 | 58 | 0.050 |
Why?
| Staining and Labeling | 1 | 2001 | 106 | 0.050 |
Why?
| Ovary | 1 | 1981 | 105 | 0.050 |
Why?
| Testis | 1 | 1981 | 65 | 0.050 |
Why?
| Nose | 1 | 2000 | 42 | 0.050 |
Why?
| Data Collection | 1 | 2002 | 320 | 0.050 |
Why?
| Administration, Intravenous | 1 | 2020 | 75 | 0.050 |
Why?
| Host-Pathogen Interactions | 1 | 2021 | 143 | 0.050 |
Why?
| Microcephaly | 1 | 2000 | 44 | 0.050 |
Why?
| Cerebellar Cortex | 1 | 1980 | 7 | 0.050 |
Why?
| Goats | 1 | 1980 | 12 | 0.050 |
Why?
| Photofluorography | 1 | 1979 | 2 | 0.050 |
Why?
| Cytokines | 1 | 2003 | 677 | 0.050 |
Why?
| Pyridines | 1 | 2021 | 137 | 0.050 |
Why?
| Syndrome | 1 | 2000 | 253 | 0.050 |
Why?
| Sheep | 1 | 1980 | 88 | 0.050 |
Why?
| Respirovirus | 1 | 2019 | 1 | 0.040 |
Why?
| Orthomyxoviridae | 1 | 2019 | 6 | 0.040 |
Why?
| Metapneumovirus | 1 | 2019 | 5 | 0.040 |
Why?
| Enterovirus | 1 | 2019 | 9 | 0.040 |
Why?
| Consensus | 1 | 2020 | 157 | 0.040 |
Why?
| Respiratory Syncytial Viruses | 1 | 2019 | 16 | 0.040 |
Why?
| Cattle | 1 | 1980 | 225 | 0.040 |
Why?
| Rhinovirus | 1 | 2019 | 26 | 0.040 |
Why?
| Coronavirus | 1 | 2019 | 16 | 0.040 |
Why?
| Rats | 1 | 2006 | 3419 | 0.040 |
Why?
| Antiviral Agents | 1 | 2020 | 188 | 0.040 |
Why?
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 105 | 0.040 |
Why?
| History, 21st Century | 1 | 2018 | 62 | 0.040 |
Why?
| History, 20th Century | 1 | 2018 | 114 | 0.040 |
Why?
| Complex Mixtures | 1 | 2017 | 7 | 0.040 |
Why?
| Disease Management | 1 | 2019 | 184 | 0.040 |
Why?
| K562 Cells | 1 | 2017 | 47 | 0.040 |
Why?
| Farnesol | 1 | 2017 | 3 | 0.040 |
Why?
| Proteolysis | 1 | 2017 | 102 | 0.040 |
Why?
| HeLa Cells | 1 | 2017 | 291 | 0.040 |
Why?
| Cardiovascular Diseases | 2 | 1979 | 476 | 0.040 |
Why?
| Magnetic Resonance Imaging | 1 | 2003 | 1616 | 0.030 |
Why?
| Cell Line | 1 | 2017 | 1152 | 0.030 |
Why?
| Critical Illness | 1 | 2017 | 344 | 0.030 |
Why?
| Technology, Radiologic | 3 | 1983 | 19 | 0.030 |
Why?
| Pneumonia | 1 | 2015 | 129 | 0.030 |
Why?
| Prevalence | 2 | 2009 | 1026 | 0.030 |
Why?
| Gestational Age | 2 | 2004 | 435 | 0.030 |
Why?
| Evidence-Based Medicine | 1 | 2012 | 276 | 0.020 |
Why?
| Germany, East | 2 | 1988 | 2 | 0.020 |
Why?
| Cryptococcus | 1 | 2010 | 2 | 0.020 |
Why?
| Food Microbiology | 1 | 2009 | 48 | 0.020 |
Why?
| Food | 1 | 2009 | 69 | 0.020 |
Why?
| Antineoplastic Agents | 1 | 2018 | 1300 | 0.020 |
Why?
| Deoxycholic Acid | 1 | 2009 | 17 | 0.020 |
Why?
| Liver Function Tests | 1 | 2009 | 43 | 0.020 |
Why?
| North America | 1 | 2009 | 70 | 0.020 |
Why?
| Drug Combinations | 1 | 2009 | 128 | 0.020 |
Why?
| Lung Neoplasms | 1 | 2015 | 643 | 0.020 |
Why?
| Infusions, Intravenous | 1 | 2009 | 231 | 0.020 |
Why?
| Drug Administration Schedule | 1 | 2009 | 401 | 0.020 |
Why?
| Disease Notification | 1 | 2007 | 7 | 0.020 |
Why?
| Diagnosis, Differential | 2 | 2003 | 1141 | 0.020 |
Why?
| Survival Analysis | 1 | 2009 | 736 | 0.020 |
Why?
| Recurrence | 1 | 2009 | 692 | 0.020 |
Why?
| Los Angeles | 1 | 2006 | 25 | 0.020 |
Why?
| Ethics Committees, Research | 1 | 2006 | 18 | 0.020 |
Why?
| Leukocyte Count | 1 | 2006 | 77 | 0.020 |
Why?
| Hypercalcemia | 1 | 2007 | 36 | 0.020 |
Why?
| Multicenter Studies as Topic | 1 | 2006 | 91 | 0.020 |
Why?
| RNA, Fungal | 1 | 2006 | 30 | 0.020 |
Why?
| Referral and Consultation | 1 | 1988 | 308 | 0.020 |
Why?
| Guideline Adherence | 1 | 2007 | 148 | 0.020 |
Why?
| Research | 1 | 2006 | 117 | 0.020 |
Why?
| Quality of Health Care | 1 | 2007 | 219 | 0.020 |
Why?
| Decision Theory | 1 | 1985 | 2 | 0.020 |
Why?
| Disease Progression | 1 | 2009 | 917 | 0.020 |
Why?
| Statistics as Topic | 1 | 1985 | 102 | 0.020 |
Why?
| Transplantation Conditioning | 1 | 2005 | 87 | 0.020 |
Why?
| Blood | 1 | 2004 | 30 | 0.020 |
Why?
| Meningitis | 1 | 2003 | 24 | 0.010 |
Why?
| Blood Glucose | 1 | 2006 | 489 | 0.010 |
Why?
| Television | 2 | 1981 | 17 | 0.010 |
Why?
| Immunophilins | 1 | 2003 | 1 | 0.010 |
Why?
| Hypertension | 1 | 1988 | 565 | 0.010 |
Why?
| Follow-Up Studies | 1 | 1988 | 2390 | 0.010 |
Why?
| Brain Diseases | 1 | 2003 | 88 | 0.010 |
Why?
| RNA, Messenger | 1 | 2006 | 1203 | 0.010 |
Why?
| Sirolimus | 1 | 2003 | 65 | 0.010 |
Why?
| Heart Valve Prosthesis | 1 | 2004 | 93 | 0.010 |
Why?
| Horses | 1 | 1982 | 51 | 0.010 |
Why?
| Prosthesis-Related Infections | 1 | 2004 | 111 | 0.010 |
Why?
| Mediastinum | 1 | 1981 | 27 | 0.010 |
Why?
| Diaphragm | 1 | 1981 | 29 | 0.010 |
Why?
| Heart | 2 | 1981 | 361 | 0.010 |
Why?
| Purkinje Cells | 1 | 1980 | 22 | 0.010 |
Why?
| Microscopy, Electron | 1 | 1980 | 97 | 0.010 |
Why?
| Mass Chest X-Ray | 1 | 1974 | 1 | 0.010 |
Why?
| Quality Control | 1 | 1984 | 101 | 0.000 |
Why?
| Electronics, Medical | 1 | 1977 | 4 | 0.000 |
Why?
| Cardiac Volume | 1 | 1974 | 7 | 0.000 |
Why?
| Methods | 1 | 1974 | 66 | 0.000 |
Why?
| False Negative Reactions | 1 | 1974 | 36 | 0.000 |
Why?
| Physical Exertion | 1 | 1974 | 67 | 0.000 |
Why?
| Heart Ventricles | 1 | 1974 | 271 | 0.000 |
Why?
| Sex Factors | 1 | 1974 | 766 | 0.000 |
Why?
| Heart Diseases | 1 | 1974 | 239 | 0.000 |
Why?
|
|
Steinbach's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|